Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Virologically Suppressed People With HIV-1
NCT07028385Phase 2Completed
- Start
- Sep 2025
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of baricitinib in human immunodeficiency virus infection (HIV). Started Sep 2025; status: completed.
02
Drugs
baricitinib
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07028385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07028385.